Found: 17
Select item for more details and to access through your institution.
Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
- Published in:
- American Health & Drug Benefits, 2020, v. 13, n. 3, p. 192
- By:
- Publication type:
- Article
Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.
- Published in:
- American Health & Drug Benefits, 2016, v. 9, n. 4, p. 203
- By:
- Publication type:
- Article
Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Real-world evaluation of health-related quality of life in patients with diffuse large B-cell lymphoma based on a multinational survey.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1402992
- By:
- Publication type:
- Article
IBCL-372: Efficacy, Safety, and Patient-Reported Outcomes (PROs) of Treatments for Relapsed/Refractory Follicular Lymphoma (R/R FL) in the Third-Line or Later (3L+) Setting: A Systematic Literature Review (SLR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S406, doi. 10.1016/S2152-2650(21)01915-7
- By:
- Publication type:
- Article
ABCL-367: Efficacy, Safety, and Patient-Reported Outcomes (PROs) of Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A Systematic Literature Review (SLR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S396, doi. 10.1016/S2152-2650(21)01897-8
- By:
- Publication type:
- Article
Poster: IBCL-372: Efficacy, Safety, and Patient-Reported Outcomes (PROs) of Treatments for Relapsed/Refractory Follicular Lymphoma (R/R FL) in the Third-Line or Later (3L+) Setting: A Systematic Literature Review (SLR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S245, doi. 10.1016/S2152-2650(21)01543-3
- By:
- Publication type:
- Article
Poster: ABCL-367: Efficacy, Safety, and Patient-Reported Outcomes (PROs) of Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A Systematic Literature Review (SLR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S240, doi. 10.1016/S2152-2650(21)01508-1
- By:
- Publication type:
- Article
A Case Report of Gemella haemolysans Keratitis After Refractive Surgery.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Lifetime Costs for Treated Follicular Lymphoma Patients in the US.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 10, p. 1163, doi. 10.1007/s40273-021-01052-3
- By:
- Publication type:
- Article
Quality of Life Evaluation in Patients with Follicular Cell Lymphoma: A Real-World Study in Europe and the United States.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 8, p. 3342, doi. 10.1007/s12325-024-02882-1
- By:
- Publication type:
- Article
A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
- Published in:
- 2020
- By:
- Publication type:
- journal article
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population.
- Published in:
- Oncology & Therapy, 2024, v. 12, n. 3, p. 565, doi. 10.1007/s40487-024-00291-6
- By:
- Publication type:
- Article